ReviewCurrent oncology reports2011
Newly emerging therapies targeting viral-related lymphomas.
Review in Current oncology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Hepatitis C virus fitness can influence the extent of infection-mediated epigenetic modifications in the host cells.Frontiers in cellular and infection microbiology · 2023Article
- Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.Blood advances · 2022Article
- Role of epigenetic modification in interferon treatment of hepatitis B virus infection.Frontiers in immunology · 2022Review
- Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities.Current oncology reports · 2021Review
- Epigenetic modulation in chronic hepatitis B virus infection.Seminars in immunopathology · 2020Review
- Novel Treatments of Adult T Cell Leukemia Lymphoma.Frontiers in microbiology · 2020Review
- Review
- [Efficacy and prognostic analysis of relapsed/refractory diffuse large B-cell lymphoma patients with hepatitis B virus infection].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- Article
- Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.Nature reviews. Cancer · 2014Review
- Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile.Infectious agents and cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Gamma-(γ)-herpes virus lymphomas comprise a heterogenous group of B-cell and T-cell neoplasms most commonly associated with Epstein-Barr virus and rarely human herpes virus-8 infection. Adult T-cell leukemia/lymphoma (ATLL) is a unique disease entity caused by the human T-cell lymphotrophic virus, type 1 (HTLV-I), the only retrovirus known to cause cancer in humans. Viral lymphomas behave aggressively and disproportionally affect immunocompromised individuals and those living in underdeveloped regions. These diseases are often difficult to treat with conventional approaches. Despite recent advancements using cytotoxic, lymphoma-specific, and adoptive therapies, the long-term outcome of patients with γ-herpesvirus lymphomas occurring in severely immunocompromised patients and ATLL continues to be poor. Lytic-inducing therapies targeting NF-κB, and viral and tumor cell epigenetic mechanisms afford the advantage of exploiting the intrinsic presence of oncogenic viruses to eradicate infected tumor cells. In this review, viral-related lymphomas and newly emerging clinical approaches targeting viral latency are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.